PROF vs. EYE, BVS, AXGN, BFLY, CBLL, IRMD, AVNS, SIBN, KIDS, and SMLR
Should you be buying Profound Medical stock or one of its competitors? The main competitors of Profound Medical include National Vision (EYE), Bioventus (BVS), AxoGen (AXGN), Butterfly Network (BFLY), CeriBell (CBLL), Iradimed (IRMD), Avanos Medical (AVNS), SI-BONE (SIBN), OrthoPediatrics (KIDS), and Semler Scientific (SMLR). These companies are all part of the "medical equipment" industry.
Profound Medical vs.
National Vision (NASDAQ:EYE) and Profound Medical (NASDAQ:PROF) are both small-cap consumer staples companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends, profitability and community ranking.
47.9% of Profound Medical shares are owned by institutional investors. 2.3% of National Vision shares are owned by insiders. Comparatively, 1.5% of Profound Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profound Medical has lower revenue, but higher earnings than National Vision. National Vision is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.
National Vision has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500. Comparatively, Profound Medical has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500.
National Vision received 214 more outperform votes than Profound Medical when rated by MarketBeat users. However, 72.73% of users gave Profound Medical an outperform vote while only 65.30% of users gave National Vision an outperform vote.
National Vision has a net margin of -0.81% compared to Profound Medical's net margin of -349.41%. National Vision's return on equity of 3.52% beat Profound Medical's return on equity.
National Vision presently has a consensus target price of $13.40, suggesting a potential upside of 16.93%. Profound Medical has a consensus target price of $14.25, suggesting a potential upside of 128.00%. Given Profound Medical's stronger consensus rating and higher probable upside, analysts clearly believe Profound Medical is more favorable than National Vision.
In the previous week, National Vision had 2 more articles in the media than Profound Medical. MarketBeat recorded 4 mentions for National Vision and 2 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.94 beat National Vision's score of 0.65 indicating that Profound Medical is being referred to more favorably in the news media.
Summary
National Vision and Profound Medical tied by winning 9 of the 18 factors compared between the two stocks.
Get Profound Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for PROF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Profound Medical Competitors List
Related Companies and Tools
This page (NASDAQ:PROF) was last updated on 1/30/2025 by MarketBeat.com Staff
Free PROF Stock Alerts